Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2524 Target Snapshot

Alpha-galactosidase A · SINGLE PROTEIN · Homo sapiens

4,432Compounds
112Assays
1Approved Drugs
91.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Alpha-galactosidase A shows approved-linked disease relevance led by Fabry disease. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P06280. Start with Fabry disease, then reuse UniProt P06280 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Fabry disease, then reuse UniProt P06280 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
Fabry disease

Alpha-galactosidase A shows approved-linked disease relevance led by Fabry disease. 2 linked drugs remain visible in the same block.

Start review with Fabry disease because it currently carries approved-linked support. Linked drugs include MIGALASTAT, MIGALASTAT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Alpha-galactosidase A as ChEMBL target CHEMBL2524, mapped to UniProt P06280. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Alpha-galactosidase A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2524
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P06280
Alpha-galactosidase A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Alpha-galactosidase A is the right protein anchor across sources, using UniProt P06280 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Fabry disease is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAlpha-galactosidase A
UniProt AccessionP06280
Component TypeProtein
Sequence Length429 aa

Alpha-galactosidase A

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Alpha-galactosidase A, mapped to UniProt P06280. Sequence length is 429 aa.

Mapped IDP06280
Review nameAlpha-galactosidase A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Alpha-galactosidase A shows approved-linked disease relevance led by Fabry disease.

Approved-linked Approved
Fabry disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugMIGALASTAT
Linked drugMIGALASTAT HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Fabry disease because it currently carries approved-linked support. Linked drugs include MIGALASTAT, MIGALASTAT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseFabry disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5069.0
KI22.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL110458 7.89 IC50 13.0 Approved
CHEMBL3350086 7.28 IC50 53.0 Preclinical
CHEMBL4792854 6.7 Ki 200.0 Preclinical
CHEMBL469844 6.3 Ki 500.0 Preclinical
CHEMBL469844 6.16 IC50 690.0 Preclinical
CHEMBL4069007 5.96 IC50 1100.0 Preclinical
CHEMBL4168689 5.92 IC50 1200.0 Preclinical
CHEMBL4792854 5.92 IC50 1200.0 Preclinical
CHEMBL4793095 5.82 Ki 1500.0 Preclinical
CHEMBL4081664 5.7 Ki 2000.0 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
8
5.5
7
6.0
1
6.5
4
7.0
1
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIGALASTAT
CHEMBL110458
Approved 2016
Assay Landscape

Assay Landscape

114
Total Assays
51
Tested Compounds
2
Assay Types
Binding — 104 assays, 51 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 76 51 5.4
cell-based format 22 0
tissue-based format 4 0
assay format 2 0
Functional — 10 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine